Testosterone replacement therapy for male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests.
Testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests (see section 4.4).
Noristerat is a depot contraceptive. It is intended for short-term use when a high level of efficacy independent of possible errors by the patient is required. It has been licensed for short-term use by women whose partners undergo vasectomy, until the vasectomy is effective, and women immunised against rubella, to prevent pregnancy during the period of activity of the virus. Use after delivery or abortion: Noristerat can generally be used immediately after delivery or abortion (but see Section 4.6 'Use during lactation').
Antares Pharma has announced that it had submitted a New Drug Application (NDA) to the FDA for QuickShot Testosterone (QST),...
The FDA cautions that prescription testosterone products are approved only for men who have low testosterone levels caused by certain...
Antares Pharma announced that the FDA has accepted its New Drug Application resubmission for Tlando (testosterone undecanoate), an oral treatment for testosterone replacement therapy.
Clarus Therapeutics announced that the FDA has approved Jatenzo (testosterone undecanoate capsules for oral use) (CIII) for testosterone replacement therapy...
Antares Pharma announced 12 week efficacy and 52 week safety results from the phase III clinical study (QST-13-003) evaluating testosterone...